Nebenwirkungen · CellCept
CellCept 250 mg hard capsules · Abschnitt 4.8 · PDF-Seite 14
HOS-085222 · Präparat HOS-083095
Malignancies Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. Hepatic transplant patients were followed for at least 1 year, but less than 3 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage cfbd7ff22f703ec70c51630dc6f79438e99977d3a3826658d819d24f5d1626a2 · Zeichen 11361–11856 im Abschnitt